Scientists may have found a way to extend lifespan without strict dieting; here's what the research shows
For centuries, humanity has pursued the secret to a longer life through alchemy, mythology, and, more recently, science. While the philosopher's stone remains a myth, researchers have discovered a reliable method to
extend lifespan
in animals: eating less.
Tired of too many ads? go ad free now
Known as
dietary restriction
, this practice triggers biological mechanisms that slow aging and improve longevity. However, strict dieting is difficult and unsustainable for many. The pressing question now is whether we can replicate these benefits without giving up the joy of food. Could science develop treatments that mimic the effects of calorie restriction, offering a longer, healthier life—without constant hunger?
Can a pill help you live longer without dieting? Science says maybe
In the last decade, researchers have studied molecules that imitate the biological impacts of eating less.
Two of the most researched compounds are rapamycin and metformin. These compounds hold the promise of increasing lifespan without the physiological and psychological strain of constant dieting.
A new study led by researchers in the
compared the impact of these drugs to that of dietary restriction. The findings were illuminating rapamycin showed life-extending effects nearly as consistent as eating less, while metformin did not produce the same longevity benefits.
Why eating less works so well
Dietary restriction has been the gold standard of anti-ageing research, when researchers first learned that laboratory rats fed a lower-calorie diet lived longer than their normally fed counterparts. Since then, many more have established that consuming fewer calories through portion control or intermittent fasting is able to extend life in a range of different species.
Nonetheless, strict dieting is hard to keep to, and too much restriction will cause harm to one's health.
Tired of too many ads? go ad free now
That is why scientists are keen to discover alternatives that provide the same benefits with fewer drawbacks.
How Rapamycin and Metformin became anti-aging contenders
Rapamycin, which was initially identified in Easter Island soil in the 1970s, is a potent immunosuppressant drug utilised to suppress organ transplant rejection. Its anti-aging applications result from its capacity to inhibit a primary molecular switch (mTOR) that informs cells that nutrients are abundant.
By suppressing this message, rapamycin mimics the action of dietary deprivation at the cell level. Actually, a combination of rapamycin with another medication, trametinib, has been found to further prolong the lifespan of mice.
Metformin is a compound found in the French lilac plant that is commonly prescribed to manage blood sugar levels in individuals with type 2 diabetes. Like rapamycin, it targets the body's nutrient-sensing mechanisms.
With its extensive record of safety and widespread use, it's been a potential life-extending candidate.
Yet the review of 167 studies involving eight vertebrate animals—from fish to rats—found no persistent evidence that metformin prolonged lifespan. This would indicate it might not be able to deliver all the benefits of dietary restriction, at least singly.
Which works best: Eating less or taking a pill?
Three interventions in the research:
Dietary restriction (reducing intake)
Rapamycin
Metformin
And the results were unequivocal:
Dietary restriction is still the most persistent way to increase lifespan.
Rapamycin stands close second, with promising results in several species and both sexes.
Metformin, as it happens, failed to produce consistent benefits.
According to the research, this places rapamycin among the most exciting leads in the quest for effective anti-ageing treatments.
The future of aging is promising—but still experimental
Though aging is not a disease, it is the main risk factor for most chronic diseases, such as cancer, dementia, and cardiovascular disease. Slowing aging—albeit modestly—may result in healthier longer lives and lower healthcare expenditures, particularly as populations globally become older. All that said, some cautionary results should be noted. A few studies actually indicated shortened lifespan with rapamycin or dietary restriction.
And the majority of studies have been conducted in lab animals not humans.
Co-lead researcher Dr. Edward Ivimey-Cook from the University of Glasgow emphasized, 'While our findings don't advocate for widespread Rapamycin use just yet, they do reinforce the need for continued research into its potential for promoting
healthy aging
. This also opens up broader conversations around the development of longevity-focused treatments.'
Supporting this view, Dr. Sultanova noted, 'Our results highlight drug repurposing as a promising strategy for enhancing both healthspan and lifespan.' Both Rapamycin and Metformin are currently undergoing human clinical trials, with definitive results yet to be released.
*Disclaimer:
This article is intended for informational purposes only and should NOT be interpreted as medical advice. While current research on drugs like rapamycin and metformin shows potential in extending lifespan in animal models, these findings are NOT yet conclusive for humans.
Always consult a qualified healthcare professional before considering any medical treatment or lifestyle change related to longevity or disease prevention.
Also Read |
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
8 hours ago
- Time of India
French scientists find new blood type in Guadeloupe woman
Basse-Terre: A French woman from the Caribbean island of Guadeloupe has been identified as the only known carrier of a new blood type, dubbed "Gwada negative," France's blood supply agency has announced. The announcement was made 15 years after researchers received a blood sample from a patient who was undergoing routine tests ahead of surgery, the French Blood Establishment (EFS) said on Friday. "The EFS has just discovered the 48th blood group system in the world!" the agency said in a statement on social network LinkedIn. "This discovery was officially recognised in early June in Milan by the International Society of Blood Transfusion (ISBT)." The scientific association had until now recognised 47 blood group systems . Thierry Peyrard, a medical biologist at the EFS involved in the discovery, told AFP that a "very unusual" antibody was first found in the patient in 2011. However, resources at the time did not allow for further research, he added. Scientists were finally able to unravel the mystery in 2019 thanks to " high-throughput DNA sequencing ", which highlighted a genetic mutation, Peyrard said. The patient, who was 54 at the time and lived in Paris, was undergoing routine tests before surgery when the unknown antibody was detected, Peyrard said. This woman "is undoubtedly the only known case in the world," said the expert. "She is the only person in the world who is compatible with herself," he said. Peyrard said the woman inherited the blood type from her father and mother, who each had the mutated gene. The name "Gwada negative", which refers to the patient's origins and "sounds good in all languages", has been popular with the experts, said Peyrard. The ABO blood group system was first discovered in the early 1900s. Thanks to DNA sequencing the discovery of new blood groups has accelerated in recent years. Peyrard and colleagues are now hoping to find other people with the same blood group. "Discovering new blood groups means offering patients with rare blood types a better level of care," the EFS said. cre-tmt-as/yad
The Hindu
9 hours ago
- The Hindu
French scientists find new blood type in Guadeloupe woman
A French woman from the Caribbean island of Guadeloupe has been identified as the only known carrier of a new blood type, dubbed "Gwada negative," France's blood supply agency has announced. The announcement was made 15 years after researchers received a blood sample from a patient who was undergoing routine tests ahead of surgery, the French Blood Establishment (EFS) said on Friday. "The EFS has just discovered the 48th blood group system in the world!" the agency said in a statement on social network LinkedIn. "This discovery was officially recognised in early June in Milan by the International Society of Blood Transfusion (ISBT)." The scientific association had until now recognised 47 blood group systems. Thierry Peyrard, a medical biologist at the EFS involved in the discovery, told AFP that a "very unusual" antibody was first found in the patient in 2011. However, resources at the time did not allow for further research, he added. Scientists were finally able to unravel the mystery in 2019 thanks to "high-throughput DNA sequencing", which highlighted a genetic mutation, Peyrard said. The patient, who was 54 at the time and lived in Paris, was undergoing routine tests before surgery when the unknown antibody was detected, Peyrard said. This woman "is undoubtedly the only known case in the world," said the expert. "She is the only person in the world who is compatible with herself," he said. Peyrard said the woman inherited the blood type from her father and mother, who each had the mutated gene. The name "Gwada negative", which refers to the patient's origins and "sounds good in all languages", has been popular with the experts, said Peyrard. The ABO blood group system was first discovered in the early 1900s. Thanks to DNA sequencing the discovery of new blood groups has accelerated in recent years. Peyrard and colleagues are now hoping to find other people with the same blood group. "Discovering new blood groups means offering patients with rare blood types a better level of care," the EFS said.
Time of India
10 hours ago
- Time of India
Scientists may have found a way to extend lifespan without strict dieting; here's what the research shows
For centuries, humanity has pursued the secret to a longer life through alchemy, mythology, and, more recently, science. While the philosopher's stone remains a myth, researchers have discovered a reliable method to extend lifespan in animals: eating less. Tired of too many ads? go ad free now Known as dietary restriction , this practice triggers biological mechanisms that slow aging and improve longevity. However, strict dieting is difficult and unsustainable for many. The pressing question now is whether we can replicate these benefits without giving up the joy of food. Could science develop treatments that mimic the effects of calorie restriction, offering a longer, healthier life—without constant hunger? Can a pill help you live longer without dieting? Science says maybe In the last decade, researchers have studied molecules that imitate the biological impacts of eating less. Two of the most researched compounds are rapamycin and metformin. These compounds hold the promise of increasing lifespan without the physiological and psychological strain of constant dieting. A new study led by researchers in the compared the impact of these drugs to that of dietary restriction. The findings were illuminating rapamycin showed life-extending effects nearly as consistent as eating less, while metformin did not produce the same longevity benefits. Why eating less works so well Dietary restriction has been the gold standard of anti-ageing research, when researchers first learned that laboratory rats fed a lower-calorie diet lived longer than their normally fed counterparts. Since then, many more have established that consuming fewer calories through portion control or intermittent fasting is able to extend life in a range of different species. Nonetheless, strict dieting is hard to keep to, and too much restriction will cause harm to one's health. Tired of too many ads? go ad free now That is why scientists are keen to discover alternatives that provide the same benefits with fewer drawbacks. How Rapamycin and Metformin became anti-aging contenders Rapamycin, which was initially identified in Easter Island soil in the 1970s, is a potent immunosuppressant drug utilised to suppress organ transplant rejection. Its anti-aging applications result from its capacity to inhibit a primary molecular switch (mTOR) that informs cells that nutrients are abundant. By suppressing this message, rapamycin mimics the action of dietary deprivation at the cell level. Actually, a combination of rapamycin with another medication, trametinib, has been found to further prolong the lifespan of mice. Metformin is a compound found in the French lilac plant that is commonly prescribed to manage blood sugar levels in individuals with type 2 diabetes. Like rapamycin, it targets the body's nutrient-sensing mechanisms. With its extensive record of safety and widespread use, it's been a potential life-extending candidate. Yet the review of 167 studies involving eight vertebrate animals—from fish to rats—found no persistent evidence that metformin prolonged lifespan. This would indicate it might not be able to deliver all the benefits of dietary restriction, at least singly. Which works best: Eating less or taking a pill? Three interventions in the research: Dietary restriction (reducing intake) Rapamycin Metformin And the results were unequivocal: Dietary restriction is still the most persistent way to increase lifespan. Rapamycin stands close second, with promising results in several species and both sexes. Metformin, as it happens, failed to produce consistent benefits. According to the research, this places rapamycin among the most exciting leads in the quest for effective anti-ageing treatments. The future of aging is promising—but still experimental Though aging is not a disease, it is the main risk factor for most chronic diseases, such as cancer, dementia, and cardiovascular disease. Slowing aging—albeit modestly—may result in healthier longer lives and lower healthcare expenditures, particularly as populations globally become older. All that said, some cautionary results should be noted. A few studies actually indicated shortened lifespan with rapamycin or dietary restriction. And the majority of studies have been conducted in lab animals not humans. Co-lead researcher Dr. Edward Ivimey-Cook from the University of Glasgow emphasized, 'While our findings don't advocate for widespread Rapamycin use just yet, they do reinforce the need for continued research into its potential for promoting healthy aging . This also opens up broader conversations around the development of longevity-focused treatments.' Supporting this view, Dr. Sultanova noted, 'Our results highlight drug repurposing as a promising strategy for enhancing both healthspan and lifespan.' Both Rapamycin and Metformin are currently undergoing human clinical trials, with definitive results yet to be released. *Disclaimer: This article is intended for informational purposes only and should NOT be interpreted as medical advice. While current research on drugs like rapamycin and metformin shows potential in extending lifespan in animal models, these findings are NOT yet conclusive for humans. Always consult a qualified healthcare professional before considering any medical treatment or lifestyle change related to longevity or disease prevention. Also Read |
